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Abstract
Background: Diabetes is one of the most prevalent metabolic 
diseases. Irisin (FNDC5 protein) is involved in the new strategy 
of combating type 2 diabetes. In the liver, the antidiabetic 
mechanism of silymarin at the molecular level is unknown. 
This study investigated the effects of silymarin on irisin and the 
related gene expression and oxidative stress status in the liver of 
type 2 diabetic rats.
Methods: Thirty-six rats were divided into 6 groups (n=6 
each) by simple randomization: control, control+silymarin 
(60 mg/kg daily in normal saline orally for 60 days), 
control+silymarin (120 mg/kg daily in normal saline orally for 
60 days), diabetic, diabetic+silymarin (60 mg/kg daily for 60 
days), and diabetic+silymarin (120 mg/kg daily for 60 days). 
Biochemical parameters were measured by spectrophotometric 
and immunoassay methods, and quantitative polymerase chain 
reaction was used to evaluate gene expression. The data were 
analyzed by one-way ANOVA, followed by the Tukey test, 
using SPSS software, version 16.0. The results were considered 
statistically significant at a P value less than 0.05. 
Results: In the diabetic rats treated with silymarin (60 and 
120 mg/kg), by comparison with the diabetic group, body 
weight (P=0.04 and P=0.02), insulin (P<0.001), expression of 
PGC-1α  (P=0.04 and P=0.02), expression of FNDC5 (P=0.03 
and P=0.01),  and concentration of irisin in the liver (P=0.02 
and P=0.01) and serum (P<0.001) were significantly increased, 
whereas the levels of glucose (P<0.001), HOMA-IR (P=0.03 and 
P=0.01), and liver injury markers (P<0.001) were significantly 
reduced. Oxidative stress status and histopathological changes 
were improved in the treated groups.  
Conclusion: These results suggest that silymarin because of 
its ability to upregulate irisin and antioxidant effects can be 
considered an antidiabetic agent. 
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What’s Known
• Several previous studies have 
shown that silymarin is widely used in 
liver diseases.
• Silymarin is a potent free radical 
scavenger.
What’s New
• This is the first study on the effects 
of silymarin irisin expression in rats with 
type 2 diabetes.
• PGC-1α  and FNDC5 mRNA 
expressions are induced by silymarin.
• Silymarin improves oxidative 
status in the liver tissue of diabetic rats.
Introduction
Diabetes mellitus (DM), as a chronic disease, is one of the major 
public health problems. Reduced insulin secretion or resistance to 
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its function has a role in the creation of DM. The 
incidence of DM in the world was estimated to be 
4% in 2010 and is expected to have amounted to 
5.4% by 2025.1 DM is the leading cause of liver 
disorders. In diabetic patients, a wide spectrum 
of liver diseases such as nonalcoholic fatty liver 
disease, cirrhosis, and liver cell carcinoma are 
prevalent.2 
Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α) is a 
multifunctional regulatory transcription factor 
and plays an important role in the regulation 
of gluconeogenesis, mitochondrial biogenesis, 
and fatty acid β-oxidation in the liver. Due to 
its key role in glucose metabolism, PGC-1α is 
a very attractive target gene for antidiabetic 
therapy.3 Studies have shown that PGC-1α 
mRNA expression in insulin resistance is 
reduced.4 PGC-1α is associated with an 
increased expression of fibronectin type III 
domain containing 5 (FNDC5). Irisin is a product 
of the proteolytic breakdown of the extracellular 
domain of FNDC5. Irisin is an antidiabetic 
hormone and is involved in the liver metabolism. 
Furthermore, it has been shown that the  level 
of this hormone decreases in people with type 
2 DM. Liu et al.5 showed that the circulating 
irisin level was significantly lower in their 
diabetic patients than that in their control group. 
Research has also demonstrated that FNDC5/
irisin ameliorates glucose disorders and insulin 
resistance.6
Recent studies have reported a negative 
relationship between irisin levels and oxidative 
stress, and in fact irisin has antioxidant 
properties.7 Hyperglycemia and insulin 
resistance cause increased generation of free 
radicals and reactive oxygen species (ROS). 
Oxidative stress plays a critical role in the 
pathogenesis of diabetic complications.8 
In recent years, the use of natural products 
has been considered for the treatment of 
hyperglycemia and complications of DM. 
Flavonoids are natural substances available 
in plants. These compounds have a high 
potential to treat a variety of disorders, including 
diabetes.9 Silymarin is a milk thistle (Silybum 
marianum) extract, which contains a mixture 
of flavonolignans. The protective effects of 
silymarin treatment as a potent ROS scavenger 
have been shown by earlier researchers.10 
Further, the hepatoprotective effects of silymarin 
by attenuating proinflammatory gene expression 
in the liver have been supported by additional 
research.11 Although the therapeutic effects of 
silymarin on DM and liver diseases have been 
shown in human and animal studies,12, 13 its 
molecular mechanisms remain to be revealed. 
Therefore, the aim of the present study was to 
investigate the protective effects of silymarin on 
irisin expression and oxidative stress in the liver 
of rats with type 2 diabetes.
Materials and Methods
Animals and Experimental Designs
The current experimental study was 
performed at the Animal House and 
Biochemistry Laboratory of Hamadan University 
of Medical Sciences (2016–2107). Thirty-six 
adult male Wistar rats (220±10 g) were used. 
The animals were kept in standard conditions 
(12-h dark/light cycle at 22±2 °C). The rats 
was divided into 6 groups (n=6 each) by simple 
randomization. Group C formed our normal 
control group. Group C+S60 and Group C+S120 
comprised control rats treated with silymarin 
(Goldaru; Isfahan, Iran) (60 and 120 mg/kg daily, 
respectively) in normal saline orally for 60 days.14 
Group D formed our diabetic control group. 
Group D+S60 and Group D+S120 comprised 
diabetic rats treated with silymarin (60 and 120 
mg/kg daily, respectively) for 60 days. At the 
end of the experimental period, body weight 
was determined. The study was approved by 
the Medical Ethics Review Board of Hamadan 
University of Medical Sciences (IR.UMSHA.
REC.1395.205).15
For the induction of type 2 diabetes, 15 
minutes after the injection of nicotinamide (NIC, 
Sigma) (120 mg/kg; i.p.), streptozotocin (STZ, 
Sigma) (60 mg/kg; i.p.) dissolved in 0.1 M of citrate 
buffer (pH 4.5) was injected in 18 overnight-
fasted rats. To confirm type 2 diabetes, after 72 
hours, the fasting blood glucose (FBS) level of 
the rats was measured with a glucometer (Accu-
Chek; Roche, Germany). The animals were 
considered diabetic when their FBS level was 
above 150 mg/dL.16 After the end of the study, 
the fasted rats were anesthetized with ketamine 
(50 mg/kg) and blood samples were collected 
from their vena cava vein for biochemical 
analysis and stored at -20 °C.  Additionally, 
the liver tissue was separated from each rat 
and cleaned with an ice-cold saline solution 
and frozen in liquid nitrogen immediately after 
separation and stored at –70°C until analysis. 
For histopathological evaluations, a small piece 
of the liver tissue was collected.
Measurement of Serum Biochemical Parameters 
Total bilirubin and liver enzymes (ALT, AST, 
and ALP) were measured  using a standard 
procedure kit (Pars Azmoon kit, Iran). The 
level of insulin was determined using the rat 
Insulin ELISA Kit (Mercodia, Uppsala, Sweden). 
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The insulin resistance index (HOMA-IR) was 
calculated as follows:17 HOMA−IR=fasting 
insulin (μU/mL)×fasting glucose (mg/dL)/405. 
The concentrations of tissue and serum irisin 
were determined using a commercial ELISA kit 
(ZellBio GmbH, Germany).
 
Assay of Hepatic Oxidative Stress Parameters
In the liver samples, malondialdehyde (MDA) 
via the Yagi method, total antioxidant capacity 
(TAC) via the Benzie and Strain method,18 total 
thiol molecules (TTM) via the Hu method, and 
total oxidant status (TOS) with the ferric-xylenol 
orange 1 (FOX1) reagent via the Erel method 
were determined. Additionally, the oxidative 
stress index (OSI) was calculated by dividing 
TOS by TAC.17 
Quantitative Real-Time Polymerase Chain 
Reaction (PCR)
Total RNA extraction was performed 
manually from the tissues using the RNX-
plus reagent (CinnaGen, Tehran, Iran). 
Complementary DNA (cDNA) synthesis was 
carried out using the PrimeScript RT reagent kit 
(TaKaRa  Biotechnology, Japan). Quantitative 
real-time PCR was performed with SYBR 
premix Ex TaqTM II (TaKaRa  Biotechnology, 
Japan) on a Roche Light Cycler 96 System 
(Roche  Life Science Deutschland GmbH, 
Sandhofer, Germany). The characteristics 
of the forward and reverse primer sequence 
(5’→3’) were listed as follows: β-actin forward: 
CCCGCGAGTACAACCTTCT and reverse: 
CGTCATCCATGGCGAACT, FNDC5 forward: 
GAGGTGCTGATCATCGTCGT and reverse: 
GAGCAAGCACTGAAAGGGTTT, and PGC-1α 
forward: GTGCAGCCAAGACTCTGTATGG and 
reverse: GTCCAGGTCATTCACATCAAGTTC. 
The fold change in the gene expression was 
investigated via the 2-ΔΔCT formula.19 
Histological Observation of the Liver Tissues
For histopathological evaluations, a small 
piece of the liver tissues was fixed in 10% 
formalin solution, dehydrated in graduate 
ethanol (50–100%), cleared in xylene, and 
embedded in paraffin. The liver sections (5 μm) 
were examined with a photomicroscope after 
staining with hematoxylin and eosin dye (H&E). 
Statistical Analysis
The results were expressed as 
means±standard deviations (SDs). The data 
were analyzed by SPSS 16 and Prism 6.0 
software (GraphPad, San Diego, CA, USA), 
and a P value less than 0.05 was considered 
statistically significant. One-way analysis 
of variance, followed by the Tukey test, was 
employed for between-group comparisons. The 
normality was checked using the Kolmogorov–
Smirnov test.
Results
General and Biochemical Parameters 
As is indicated in table 1, body weight 
decreased in the diabetic rats (Group D) 
compared to the control group (Group C) after 
8 weeks of experiment (P<0.001). Treatment 
with both doses of silymarin (60 mg/kg [P=0.04] 
and 120 mg/kg [P=0.02]) improved body weight 
compared to that in Group D.  
To study the possible protective role 
of silymarin against insulin resistance, we 
investigated the levels of serum FBS, insulin, 
and HOMA-IR. Eight weeks after the injection 
of NIC/STZ, a significant increase in FBS was 
detected in Group D in comparison to Group C 
(P<0.001). Treatment with silymarin with both 
doses of 60 and 120 mg/kg caused a significant 
reduction in FBS compared to that in Group D 
(P<0.001) (table 1).
Table 1: Effects of silymarin on the rats’ body weight and biochemical parameters in the different studied groups
Parameter/ Group C
)n=6(
C+S60
)n=6(
C+S120
)n=6(
D
)n=6(
D+S60
)n=6(
D+S120
)n=6(
Final body weight (g) 297.50±18.39 288.00±18.69 289.00±19.76 a 182.50±16.94 b 215.6±14.94 b 219.83±23.69
FBS (mg/dL) 83.33±10.93 76.50±12.24 79.50±13.80 299.383±27.05 a 202.67±45.14 b 182.50±35.82 b
Insulin (µU/mL) 11.46±0.47 11.96±0.67 11.65±1.64 7.10±1.06 a 9.60±1.11 b b 9.80±0.96
HOMA-IR 2.35±0.27 2.24±0.26 2.28±0.41 5.79±0.90 a 4.71±0.64 b 4.35±0.56 b
ALT (U/L) 53.00±6.10 47.16±5.26 55.00±5.51 160.66±7.11 a 73.50±2.07 b 70.50±3.04 b
AST (U/L) 108.33±6.59 119.16±11.16 115.66±9.79 239.16±14.17 a 152.00±6.71 b 140.50±10.44 b
ALP (U/L) 250.50±19.59 267.16±20.74 270.33±21.44 730.16±41.88 a 396.50±34.56 b 431.83±24.92 b
Total bilirubin (mg/dL) 0.43±0.05 0.42±0.03 0.48±0.06 1.03±0.11 a 0.57±0.06 b 0.54±0.11  b
Results are expressed as means±SDs. C: Control; S: Silymarin; D: Diabetic; FBS: Fasting blood sugar; ALT: Alanine transaminase; 
AST: Aspartate transaminase; ALP: Alkaline phosphatase; HOMA-IR: Insulin resistance index; aSignificant compared to the 
healthy control group; bSignificant compared to the diabetic control group; Significant difference between the diabetic and control 
groups in the all the parameters (P<0.001); Significant difference between the diabetic rats treated with silymarin (60 and 120 
mg/kg) and the diabetic group in body weight (P=0.04 and P=0.02), FBS (P<0.001), insulin (P<0.001), HOMA-IR (P=0.03 and 
P=0.01), and liver injury markers (P=0.00)
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Induced type 2 diabetes caused a reduction 
in insulin concentration and an increase in 
HOMA-IR in Group D compared to Group 
C (P<0.001). Treatment with both doses of 
silymarin significantly increased the insulin level 
and reduced HOMA-IR back to the normal value 
(insulin: P<0.001; HOMA-IR: Group D+S60 and 
Group D+S120 compared to Group D; P=0.03 
and P=0.01, respectively) (table 1). 
Liver injury markers (ALT, AST, ALP, and total 
bilirubin) in the diabetic rats showed a significant 
rise by comparison with those in Group C 
(P<0.001). The increased serum liver injury 
markers in Group D were modulated after the 
administration of silymarin (P<0.001) (table 1).
Effects of Silymarin on the Oxidative Stress 
Biomarkers
As is depicted in figure 1, significant increases 
were observed in the MDA, TOS, and OSI levels 
in Group D versus Group C (P<0.001), whereas 
treatment with silymarin resulted in decreased 
levels of MDA, TOS, and OSI compared to 
Group D (P<0.001) (figure 1). The levels of TAC 
and TTM were significantly decreased in Group 
D compared to Group C (P<0.001). Treatment 
with silymarin significantly reversed TAC in the 
treated groups (Group D+S60 [P=0.04] and 
Group D+S120 [P=0.01]) and TTM in the treated 
groups (Group D+S60 [P=0.01] and Group 
D+S120 [P<0.001]) compared to Group D.
Figure 1: Effects of silymarin on liver oxidative stress parameters. The results are expressed as means±SDs.
Liver MDA (A), TTM (B), TOS (C), TAC (D) and OSI (E) contents. C: Control; S: Silymarin; D: Diabetic; MDA: Malondialdehyde; 
TTM: Total thiol molecule; TOS: Total oxidant status; TAC: Total antioxidant capacity; OSI: Oxidative stress index; aSignificant 
compared to the healthy control group; bSignificant compared to the diabetic control group; Significant difference between the 
diabetic and control groups in the all the parameters (P<0.001)
Significant difference between the diabetic rats treated with silymarin (60 and 120 mg/kg) and the diabetic group in MDA, TOS, 
and OSI (P= 0.00), TAC (P=0.04 and P=0.01), and TTM (P=0.01 and P<0.001)
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Effects of Silymarin on Gene Expression 
The expressions of PGC-1α and FNDC5 at 
the mRNA level in the liver tissues of all the 
groups were assessed. The results indicated 
that the expression of PGC-1α and FNDC5 
in Group D was significantly less than that 
in Group C (P<0.001). Silymarin caused a 
significant increase in PGC-1α and FNDC5 gene 
expression (Group D+S60 vs. Group D, PGC-1α: 
P=0.04 and FNDC5: P=0.03; Group D+S120 vs. 
Group D, PGC-1α: P=0.02 and FNDC5: P=0.01) 
(figure 2).  
Effects of Silymarin on Serum and Tissue Irisin 
Concentrations
A significant reduction in the irisin concentration 
in the liver and serum of Group D compared to 
Group C was identified (P<0.001). There was 
also a significant rise in the irisin concentration 
in Group D+S60 and Group D+S120 compared 
to Group D (liver irisin, Group D+S60 and Group 
D+S120; P=0.02 and P=0.01, respectively, and 
serum irisin [P<0.001]) (figure 2). 
Histological Observation
The liver tissues of all the control rats showed 
a normal lobular architecture with central 
veins, radiating hepatic cords, and portal triads 
containing the portal vein, hepatic artery, and 
bile duct (figure 3A).
Sections of the liver from the diabetic rats 
(figure 3 B-F) showed mild-to-severe lesions 
represented by disorganization in the hepatic 
cords, moderate centrilobular hepatocyte 
degeneration with an accumulation of lipid 
droplets in the cytoplasm of the hepatocytes, 
congestion and dilation of the sinusoids and 
central veins, infiltration of the mononuclear cells 
in the portal tracts, mild bile duct proliferation, 
and focal necrosis. Additionally, the presence of 
giant hepatocytes without distinct cell borders 
and morphological changes such as pyknosis, 
karyorrhexis, and chromatolysis were constant 
features in the centrilobular area. 
The livers of the treated diabetic rats 
(figure 3 G and H) with low and high doses of 
silymarin showed improvement in the structure 
Figure 2: Effect of silymarin on PGC-1α, FNDC5, and irisin.  The results are expressed as means±SDs. A( PGC-1α mRNA levels 
in the liver; B( FNDC5 mRNA levels in the liver; C( liver irisin, and D( serum irisin concentration. C: Control; S: Silymarin; D: 
Diabetic; FNDC5: Fibronectin type III domain-containing protein 5; aSignificant compared to the healthy control group; bSignificant 
compared to the diabetic control group; Significant difference between the diabetic and control groups in the all the parameters 
(P<0.001); Significant difference between the treated diabetic rats (60 and 120 mg/kg) and the diabetic groups in PGC-1α (P=0.04 
and P=0.02), FNDC5 (P=0.03 and P=0.01), liver irisin (P=0.02 and P=0.01), and serum irisin (P<0.001)
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of the hepatic tissue compared to those of the 
untreated diabetic rats. 
Discussion
DM is a global problem with a close correlation 
with liver diseases.2 Silymarin therapies have 
been shown in some studies to possess 
antidiabetic and hepatoprotective properties.5 
The results of the present study showed that 
silymarin inhibited NIC/STZ-induced weight 
loss and oxidative stress, attenuated insulin 
resistance, reduced deleterious hepatic injuries, 
and induced the production of PGC-1α and 
FNDC5/irisin in the hepatic tissues of our 
diabetic rats. 
In our study, the body weight of the untreated 
diabetic group decreased significantly. This 
reduction in body weight can be due to a 
breakdown of tissue proteins in diabetic rats.20 
We found that silymarin was able to inhibit 
body weight reduction during an 8-week 
period following the administration of NIC/STZ, 
probably due to the protective role of silymarin 
in controlling muscle atrophy (i.e., reversal 
of gluconeogenesis).21 Studies have shown 
that silymarin can restore weight and improve 
glucose and insulin levels in diabetic rats.22 
Silymarin is widely used in liver diseases all 
over the world for its hepatoprotective potential. 
In the last decade, other beneficial capabilities 
of silymarin administration such as antioxidant, 
anti-inflammatory, immunomodulatory, and 
liver-regenerating capacities were emphasized 
by experimental research and clinical trials. 
Silymarin inhibits liver injury by maintaining 
the integrity of the plasma membrane, inhibits 
the secretion of liver enzymes in blood, and 
suppresses apoptosis in hepatocytes.10 Shaker et 
al.23 showed that the use of silymarin (100 mg/kg) 
in the treatment of carbon tetrachloride-induced 
liver damage (2 mL/kg) significantly reduced the 
liver enzyme activity in the rat serum. Similarly, 
in the current study, we recorded a decrease in 
the rats’ serum ALT, AST, ALP, and total bilirubin 
levels after treatment with silymarin. 
The liver plays an important role in regulating 
glucose concentration in physiological and 
pathological states such as in DM. In type 
2 DM, insulin resistance in the liver leads to 
hyperglycemia and further distortion of glucose 
metabolism.24 Hyperglycemia inhibits complex 
III and leads to the production of ROS in the 
liver and other organs. Oxidative stress also 
plays a key role in the pathology of diabetes.25 
Silymarin possesses antioxidant properties. It 
prevents lipid peroxidation, inhibits glutathione 
reduction, and induces antioxidant enzymes 
activity.26 These effects are determined largely 
by the presence of a β ring catechol group 
(dihydroxylated β- ring), capable of donating 
hydrogen electrons that stabilize ROS, and a 
high phenolic content. Additionally, the presence 
of 2’,3’ unsaturation in conjugation with a 4-oxo-
function in the C ring and the presence of 
functional groups capable of binding transition 
metal ions such as iron may also be responsible 
for the antioxidant nature of silymarin.5 In the 
present study, treatment with silymarin reduced 
the level of oxidative stress markers (MDA, 
TOS, and OSI) and increased antioxidants (TTM 
and TAC) in the liver tissue. The antioxidant 
properties of silymarin are a strong justification 
for its hepatoprotective effects.27 Oxidative stress 
plays a key role in triggering hepatic damage 
Figure 3: Histopathological observation in the liver tissues 
of the experimental rats. A) Normal rat: A normal lobular 
pattern is seen with a centrilobular vein and radiating 
irregular anastomosing plates of the hepatocytes with 
intervening sinusoids (H&E, scale bar=100 µm), B) Diabetic 
rat: Congestion and dilation of the sinusoids (arrows) (scale 
bar=25 µm), C) Diabetic rat: Disorganization of the hepatic 
cords and the presence of degenerated hepatocytes with 
macrovesicular steatosis (stars) (scale bar=25 µm), D) 
Treated diabetic rat: Cytoplasmic vacuoles in the cytoplasm 
(scale bar=25 µm), E) Diabetic rat: Focal necrosis (stars) 
(scale bar=100 µm), F) Treated diabetic rat: Disorganization 
of the hepatic cords and mild hepatocyte degeneration 
(star) (scale bar=100 µm), G) Diabetic rat: Mild-to-moderate 
infiltration of the mononuclear cells around the portal area 
(arrow) (scale bar=25 µm), H) Treated diabetic rat: Normal 
portal area without mononuclear cell infiltration (scale 
bar=25 µm)
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by inducing alterations in lipids and proteins 
as well as structural and pathway changes that 
control normal and physiological functions. 
These pathways such as PGC-1α regulate 
gene transcription, mitochondrial biogenesis, 
and protein expression in the liver tissue.28, 
29 Research has shown that the expression 
of PGC-1α is reduced in muscle samples 
from patients with type 2 DM. Furthermore, in 
nondiabetic subjects with a family history of DM, 
there is a significant 34% reduction in PGC-1α 
mRNA expression compared to individuals 
with no family history of diabetes. Therefore, 
diminished PGC-1α expression levels might be 
a marker of a prediabetic condition.30 On the 
other hand, it has been demonstrated that the 
increased expression of this gene may improve 
glucose homeostasis and reduce insulin 
resistance.31 Barbagallo et al.32 reported that 
the PGC-1α gene expression in adipose tissue-
derived mesenchymal stem cells is induced by 
silibinin. Similarly, in the current study, in line 
with other studies, we demonstrated that NIC/
STZ decreased PGC-1α mRNA expression. We 
observed that the PGC-1α gene expression was 
upregulated by silymarin treatment. A possible 
mechanism for the effects of silymarin on the 
PGC-1α gene expression is a hypoglycemic and 
antioxidant effect.
FNDC5 is a downstream molecule and 
the target of PGC-1α; thus, the expression of 
FNDC5 and the synthesis of the transmembrane 
FNDC5 protein are induced by PGC-1α. Irisin is 
a product of FNDC5. The concentration of irisin 
in plasma has been reported to decrease by 72% 
in PGC-1α- deficient mice.33 Irisin has attracted 
remarkable interest because of its putative 
therapeutic potential for obesity and diabetes. 
Several studies have shown an association 
between decreased levels of circulating irisin 
and insulin resistance or diabetes.34 Studies 
have revealed lower concentrations of irisin 
in patients with type 2 DM.35 In an animal 
study, Bostrom  et al.36  showed that irisin was 
able to improve glucose tolerance and insulin 
sensitivity. Huh et al.37 reported a correlation 
between irisin and glucose in humans. Previous 
research has shown that irisin inhibits palmitic 
acid-induced apoptosis in liver cells via inhibiting 
oxidative stress status and inflammation is 
mediated by the inhibition of protein arginine 
methyltransferase-3, indicating a relationship 
between oxidative stress and irisin.38 Our results 
in the current study revealed a significant 
diminution of FNDC5 mRNA and irisin protein in 
the liver and serum of the diabetic group. For the 
first time, the findings of the present investigation 
showed that treatment with silymarin 
significantly induced mRNA transcripts and the 
protein of irisin in the hepatic tissue and serum 
of treated diabetic rats. Previous studies have 
demonstrated that adenovirus- upregulated irisin 
improves hepatic steatosis and insulin resistance 
in genetic-induced obese mice.39 Another study 
also showed that the upregulation of irisin was 
associated with a reduction in oxidative stress.7 
Recent data have shown that silymarin interacts 
with transcription factors and subsequent 
alter gene expression and protein synthesis.22 
Therefore, one of the main mechanisms of the 
hepatoprotective effects of silymarin in the liver 
may be its antioxidant effects. Indeed, via these 
properties, silymarin can increase FNDC5/irisin 
production. 
Since irisin is produced and secreted by 
different tissues, the increased serum irisin 
concentration in our study may have been due 
to the effects of silymarin on various tissues 
including liver, muscle, and heart. This is a topic 
for further research. In addition, the molecular 
mechanisms of the expression, secretion, 
and actions of irisin on the liver tissue remain 
unknown and require further studies.
The results of  histopathological studies 
strongly support the  outcome of our study. 
Histopathological research has presented no 
evidence of bile duct proliferation, mononuclear 
cell infiltration, or parenchymal cell necrosis in 
the livers of treated diabetic rats. A comparison 
between low- and high-dose silymarin and the 
histological alterations were similar in both 
treatment groups.
In order to select the appropriate doses in the 
present study, we considered the results of other 
studies and reports that effects of silymarin are 
dose dependent.5 We selected the dose of 60 
mg/kg because it has been demonstrated to be 
the suitable dose for hepatoprotective effects.40 
The 120 mg/kg dose is the high dose used in 
other studies to show its ability to reveal diabetic 
changes.14 Accordingly, we concluded that a 
comparison between these 2 doses would 
enable us to find the optimal therapeutic dose 
for the prevention of DM complications.
In our study, the administration of silymarin 
(60 and 120 mg/kg) was chronic and long-
term. Our normal group rats adapted their 
body to gradual changes and maintained 
their homeostasis. We detected no significant 
difference between the normal groups receiving 
silymarin and the control group. Had we tried a 
sudden administration of high doses of silymarin, 
we might have observed significant changes in 
the controls receiving silymarin by comparison 
with the control group. At any rate, our results 
demonstrated no significant changes in all the 
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factors between the 2 treatment control groups 
and the untreated control group: this confirms 
that the silymarin doses used did not have toxic 
effects on the rats’ livers. Similarly, Soto et al.22 
reported no significant difference in insulin and 
glucose levels after treating their control group 
with silymarin (200 mg/kg for 30 days) compared 
to their healthy control group. 
The strength of the current study is that it is 
the first report on the effects of silymarin on the 
irisin hormone. The major limitation of our study, 
however, is that financial constraints precluded 
the use of some additional experiments such 
as western blotting for PGC-1α, direct assay of 
ROS, and antioxidant enzyme activity. 
Conclusion
Liver injury is a serious complication among 
patients with DM. We showed that silymarin 
significantly decreased FBS and increased 
the insulin level; hence, it was able to improve 
HOMA-IR.  Furthermore, silymarin augmented 
oxidative stress status in the liver tissue. The 
present study also showed that not only did 
silymarin increase the PGC-1α and FNDC5 
gene expression in diabetic rat liver tissues 
but also it raised the irisin concentration in the 
liver and serum of diabetic rats. We concluded 
that one of the principle mechanisms of the 
hepatoprotective effects of silymarin on the liver 
might be its antioxidant effects. However, more 
research is required to elucidate the molecular 
mechanisms of the effects of silymarin. 
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